© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 23, 1897-1909,
December 6, 2000
© 2000 Oxford University Press
Synergistic Cytotoxicity in Solid Tumor Cell Lines Between N-(4-Hydroxyphenyl)retinamide and Modulators of Ceramide Metabolism
Affiliations of authors: B. J. Maurer, C. P. Reynolds, Division of Hematology-Oncology, Childrens Hospital Los Angeles and Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles; L. Melton, C. Billups, Division of Hematology-Oncology, Childrens Hospital Los Angeles; M. C. Cabot, The John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA.
Correspondence to: C. Patrick Reynolds, M.D., Ph.D., Division of Hematology-Oncology, MS #57, Childrens Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027 (e-mail: preynolds{at}chla.usc.edu).
Background: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways. Our goal was to determine if several molecules that inhibit enzymes involved in ceramide metabolism—L-threo-dihydrosphingosine (safingol), d,l-threo-1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol (PPMP), and tamoxifen—enhanced 4-HPR-mediated cytotoxicity and/or affected ceramide levels. Methods: Cellular lipids were quantified by radiolabeling and thin-layer chromatography. Cytotoxicity and cytotoxic synergy (expressed as combination index, where combination index <1 indicates synergy and >1 indicates antagonism) were measured in cultured cancer cell lines with the use of a fluorescence-based assay of cell viability employing digital imaging microscopy. Statistical tests were two-sided. Results: 4-HPR increased ceramide levels by de novo synthesis. Safingol (1–4 µM) was incorporated into a stereochemical variant of ceramide and synergized with a 3 : 1 molar ratio of 4-HPR (3–12 µM), to produce a 100-fold to 10 000-fold (2 to 4 logs) increase in cytotoxicity relative to 4-HPR alone in neuroblastoma (combination index <0.1), lung (combination index <0.1–0.2), melanoma (combination index <0.1–0.2), prostate (combination index <0.1–1.0), colon (combination index 0.1–0.3), breast (combination index = 0.1–0.5), and pancreas (combination index = 0.2) cell lines, including p53 mutant and alkylator-resistant cell lines. The 4-HPR and safingol combination was cytotoxic in low-oxygen conditions and was minimally toxic to normal fibroblasts and bone marrow myeloid progenitor cells. Addition of agents that retard ceramide glucosylation and/or acylation, such as PPMP or tamoxifen, to 4-HPR or to the combination of 4-HPR and safingol further increased cytotoxicity to tumor cells. Conclusions: Combinations of 4-HPR and modulators of ceramide metabolism may form the basis for a novel chemotherapy that is functional under hypoxic conditions (e.g., such as those within tumors) and is p53 independent and caspase independent.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. H. Kang, Z. Wan, Y. H. Kang, R. Sposto, and C. P. Reynolds Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation J Natl Cancer Inst, April 16, 2008; 100(8): 580 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Sreekumar, J. Zhou, J. Sohn, C. Spee, S. J. Ryan, B. J. Maurer, R. Kannan, and D. R. Hinton N-(4-hydroxyphenyl) Retinamide Augments Laser-Induced Choroidal Neovascularization in Mice Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1210 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Maurer, O. Kalous, D. W. Yesair, X. Wu, J. Janeba, V. Maldonado, V. Khankaldyyan, T. Frgala, B.-C. Sun, R. T. McKee, et al. Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex Clin. Cancer Res., May 15, 2007; 13(10): 3079 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Frgala, O. Kalous, R. T. Proffitt, and C. P. Reynolds A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations Mol. Cancer Ther., March 1, 2007; 6(3): 886 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Villablanca, M. D. Krailo, M. M. Ames, J. M. Reid, G. H. Reaman, and C. P. Reynolds Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709) J. Clin. Oncol., July 20, 2006; 24(21): 3423 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schulz, T. Mousallem, M. Venkataramani, D.-A. Persaud-Sawin, A. Zucker, C. Luberto, A. Bielawska, J. Bielawski, J. C. M. Holthuis, S. M. Jazwinski, et al. The CLN9 Protein, a Regulator of Dihydroceramide Synthase J. Biol. Chem., February 3, 2006; 281(5): 2784 - 2794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Thon, H. Mohlig, S. Mathieu, A. Lange, E. Bulanova, S. Winoto-Morbach, S. Schutze, S. Bulfone-Paus, and D. Adam Ceramide mediates caspase-independent programmed cell death FASEB J, December 1, 2005; 19(14): 1945 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Gouaze, Y.-Y. Liu, C. S. Prickett, J. Y. Yu, A. E. Giuliano, and M. C. Cabot Glucosylceramide Synthase Blockade Down-Regulates P-Glycoprotein and Resensitizes Multidrug-Resistant Breast Cancer Cells to Anticancer Drugs Cancer Res., May 1, 2005; 65(9): 3861 - 3867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Stover, A. Sharma, G. P. Robertson, and M. Kester Systemic Delivery of Liposomal Short-Chain Ceramide Limits Solid Tumor Growth in Murine Models of Breast Adenocarcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3465 - 3474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Myatt, C. P.F. Redfern, and S. A. Burchill p38MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death Clin. Cancer Res., April 15, 2005; 11(8): 3136 - 3148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yang and C. P. Reynolds Tirapazamine Cytotoxicity for Neuroblastoma Is p53 Dependent Clin. Cancer Res., April 1, 2005; 11(7): 2774 - 2780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. LOVAT, M. CORAZZARI, B. GORANOV, M. PIACENTINI, and C. P. F. REDFERN Molecular Mechanisms of Fenretinide-Induced Apoptosis of Neuroblastoma Cells Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dmitrovsky Fenretinide Activates a Distinct Apoptotic Pathway J Natl Cancer Inst, September 1, 2004; 96(17): 1264 - 1265. [Full Text] [PDF]
|
|
|
|
|
|
P. E. Lovat, F. Di Sano, M. Corazzari, B. Fazi, R. P. Donnorso, A. D. J. Pearson, A. G. Hall, C. P. F. Redfern, and M. Piacentini Gangliosides Link the Acidic Sphingomyelinase-Mediated Induction of Ceramide to 12-Lipoxygenase-Dependent Apoptosis of Neuroblastoma in Response to Fenretinide J Natl Cancer Inst, September 1, 2004; 96(17): 1288 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Batra, C. P. Reynolds, and B. J. Maurer Fenretinide Cytotoxicity for Ewing's Sarcoma and Primitive Neuroectodermal Tumor Cell Lines Is Decreased by Hypoxia and Synergistically Enhanced by Ceramide Modulators Cancer Res., August 1, 2004; 64(15): 5415 - 5424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zhang, C. R. Dass, E. Sumithran, N. Di Girolamo, L.-Q. Sun, and L. M. Khachigian Effect of Deoxyribozymes Targeting c-Jun on Solid Tumor Growth and Angiogenesis in Rodents J Natl Cancer Inst, May 5, 2004; 96(9): 683 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gouaze, J. Y. Yu, R. J. Bleicher, T.-Y. Han, Y.-Y. Liu, H. Wang, M. M. Gottesman, A. Bitterman, A. E. Giuliano, and M. C. Cabot Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy Mol. Cancer Ther., May 1, 2004; 3(5): 633 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stover and M. Kester Liposomal Delivery Enhances Short-Chain Ceramide-Induced Apoptosis of Breast Cancer Cells J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 468 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dragusin, C. Gurgui, G. Schwarzmann, J. Hoernschemeyer, and G. van Echten-Deckert Metabolism of the unnatural anticancer lipid safingol, L-threo-dihydrosphingosine, in cultured cells J. Lipid Res., September 1, 2003; 44(9): 1772 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Goto, B. Yang, D. Petersen, K. A. Pepper, P. A. Alfaro, D. B. Kohn, and C. P. Reynolds Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines Mol. Cancer Ther., September 1, 2003; 2(9): 911 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Shabbits, Y. Hu, and L. D. Mayer Tumor Chemosensitization Strategies Based on Apoptosis Manipulations Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813. [Full Text] [PDF]
|
|
|
|
|
|
N. Keshelava, D. Tsao-Wei, and C. P. Reynolds Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53 Clin. Cancer Res., August 1, 2003; 9(9): 3492 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Di Sano, B. Fazi, G. Citro, P. E. Lovat, G. Cesareni, and M. Piacentini Glucosylceramide Synthase and Its Functional Interaction with RTN-1C Regulate Chemotherapeutic-induced Apoptosis in Neuroepithelioma Cells Cancer Res., July 15, 2003; 63(14): 3860 - 3865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Sabichi, M. R. Modiano, J. J. Lee, Y.-M. Peng, M.-J. Xu, H. Villar, W. S. Dalton, and S. M. Lippman Breast Tissue Accumulation of Retinamides in a Randomized Short-term Study of Fenretinide Clin. Cancer Res., July 1, 2003; 9(7): 2400 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yang, N. Keshelava, C. P. Anderson, and C. P. Reynolds Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine Cancer Res., April 1, 2003; 63(7): 1520 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Erdreich-Epstein, L. B. Tran, N. N. Bowman, H. Wang, M. C. Cabot, D. L. Durden, J. Vlckova, C. P. Reynolds, M. F. Stins, S. Groshen, et al. Ceramide Signaling in Fenretinide-induced Endothelial Cell Apoptosis J. Biol. Chem., December 13, 2002; 277(51): 49531 - 49537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Houghton, P. C. Adamson, S. Blaney, H. A. Fine, R. Gorlick, M. Haber, L. Helman, S. Hirschfeld, M. G. Hollingshead, M. A. Israel, et al. Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary Clin. Cancer Res., December 1, 2002; 8(12): 3646 - 3657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-G. Kim, K.-R. You, M.-J. Liu, Y.-K. Choi, and Y.-S. Won GADD153-mediated Anticancer Effects of N-(4-Hydroxyphenyl)retinamide on Human Hepatoma Cells J. Biol. Chem., October 4, 2002; 277(41): 38930 - 38938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Simeone, S. Ekmekcioglu, L. D. Broemeling, E. A. Grimm, and A. M. Tari A Novel Mechanism by Which N-(4-hydroxyphenyl)retinamide Inhibits Breast Cancer Cell Growth: The Production of Nitric Oxide Mol. Cancer Ther., October 1, 2002; 1(12): 1009 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Lovat, S. Oliverio, M. Ranalli, M. Corazzari, C. Rodolfo, F. Bernassola, K. Aughton, M. Maccarrone, Q. D. C. Hewson, A. D. J. Pearson, et al. GADD153 and 12-Lipoxygenase Mediate Fenretinide-induced Apoptosis of Neuroblastoma Cancer Res., September 15, 2002; 62(18): 5158 - 5167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Doolittle, L. E. Abrey, N. Ferrari, W. A. Hall, E. R. Laws, R. E. McLendon, L. L. Muldoon, D. Peereboom, D. R. Peterson, C. P. Reynolds, et al. Targeted Delivery in Primary and Metastatic Brain Tumors: Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium Clin. Cancer Res., June 1, 2002; 8(6): 1702 - 1709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Metelitsa, S. D. Gillies, M. Super, H. Shimada, C. P. Reynolds, and R. C. Seeger Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on Fcgamma RII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis Blood, May 13, 2002; 99(11): 4166 - 4173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Reynolds Ras and Seppuku in Neuroblastoma J Natl Cancer Inst, March 6, 2002; 94(5): 319 - 321. [Full Text] [PDF]
|
|
|
|
|
|
F. TOSETTI, N. FERRARI, S. DE FLORA, and A. ALBINI Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents FASEB J, January 1, 2002; 16(1): 2 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Smith and B. Anderson Where to Next with Retinoids for Cancer Therapy? Clin. Cancer Res., October 1, 2001; 7(10): 2955 - 2957. [Full Text] [PDF]
|
|
|
|
|
|
C. Sanchez, M. L. de Ceballos, T. G. del Pulgar, D. Rueda, C. Corbacho, G. Velasco, I. Galve-Roperh, J. W. Huffman, S. Ramon y Cajal, and M. Guzman Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor Cancer Res., August 1, 2001; 61(15): 5784 - 5789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, and C. P. Reynolds Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines Cancer Res., August 1, 2001; 61(16): 6185 - 6193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, B. J. Maurer, C. P. Reynolds, and M. C. Cabot N-(4-Hydroxyphenyl)retinamide Elevates Ceramide in Neuroblastoma Cell Lines by Coordinate Activation of Serine Palmitoyltransferase and Ceramide Synthase Cancer Res., July 1, 2001; 61(13): 5102 - 5105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Senchenkov, D. A. Litvak, and M. C. Cabot Targeting Ceramide Metabolism--a Strategy for Overcoming Drug Resistance J Natl Cancer Inst, March 7, 2001; 93(5): 347 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Marks, M. Dominguez, K. Wu, and R. E. Pagano Identification of Active Site Residues in Glucosylceramide Synthase. A NUCLEOTIDE-BINDING/CATALYTIC MOTIF CONSERVED WITH PROCESSIVE beta -GLYCOSYLTRANSFERASES J. Biol. Chem., July 6, 2001; 276(28): 26492 - 26498. [Abstract] [Full Text] [PDF]
|
|